info@cpapstudio.co.uk
+44 7899 539620
One of the most searched questions in CPAP therapy and one that deserves a clear, complete, and honest answer for UK patients navigating their options in 2026.
The Direct Answer: What UK Law Actually Says
Under UK medical device regulations, CPAP machines are Class IIa medical devices (or Class IIb for bilevel/BiPAP devices). They are not classified as prescription-only medicines under the Human Medicines Regulations 2012, which governs drugs that require a prescription. This means a registered UK retailer can legally sell a CPAP machine directly to a member of the public.
In practice, this is exactly what happens. A number of registered UK respiratory equipment suppliers including CPAPstudio sell CPAP machines, masks, and accessories to patients who have already been diagnosed, to existing CPAP users replacing equipment, and in some circumstances to people who have not yet obtained a formal clinical diagnosis but are seeking equipment for reasons ranging from travel preparation to cost avoidance of private sleep studies.
The legal ability to purchase without a prescription does not, however, resolve the clinical questions that a prescription is designed to answer. Understanding the distinction between what is legally permitted and what is clinically advisable is the critical nuance this article addresses.
Why a Prescription Matters: What It Actually Contains
In countries such as the United States, CPAP machines are formally classified as prescription devices and cannot legally be sold without one. The UK regulatory framework is different, but the clinical information that a prescription encapsulates remains equally important regardless of whether the law requires it.
A CPAP prescription from a sleep specialist is not simply permission to purchase a machine. It contains three pieces of clinical information that are essential for effective, safe therapy:
A sleep study confirms whether you have obstructive sleep apnoea (OSA), central sleep apnoea (CSA), mixed apnoea, or another form of sleep-disordered breathing entirely. CPAP is highly effective for OSA. For central sleep apnoea, standard CPAP can be ineffective or in some cases worsen the condition a bilevel or servo-ventilation device is typically required instead. Self-treating without a diagnosis means there is a real possibility that the wrong device type is being used for the wrong condition.
CPAP therapy works by delivering air at a pressure sufficient to keep the upper airway open during sleep. Too low a pressure fails to prevent apnoeas. Too high a pressure causes its own problems aerophagia (swallowing air), central apnoea induction, discomfort, and poor sleep quality. The correct pressure is determined by a formal titration process either an in-laboratory attended study or an auto-titrating device study. Without this, self-prescribed pressure settings are guesswork, even with an Auto CPAP device.
Clinical review at one month, three months, and annually allows the prescribing team to assess therapy data, adjust settings, address mask fit issues, and identify any complications such as treatment-emergent central apnoeas a recognised phenomenon where CPAP therapy triggers central events that were not present before. Without clinical follow-up, these events may go undetected indefinitely, the patient believing their therapy is working when the objective data would tell a different story.
The Risks of Using CPAP Without a Clinical Assessment
Using a CPAP machine without a preceding clinical assessment is legal in the UK. It is not, however, without risk. The risks are not theoretical they are well-documented in sleep medicine literature and encountered regularly by clinicians dealing with patients who have self-treated before seeking formal care.
Central sleep apnoea, upper airway resistance syndrome, hypoventilation disorders, and other forms of sleep-disordered breathing can present with symptoms identical to OSA snoring, daytime sleepiness, non-restorative sleep, morning headaches. Each requires a different treatment approach. Standard CPAP applied to central sleep apnoea can increase central events in some patients. Only a sleep study distinguishes between these conditions reliably.
An Auto CPAP device set to its default wide pressure range (typically 4–20 cmH₂O) will attempt to find an appropriate pressure, but without titration data, it has no informed starting point. In patients with positional apnoea, high-altitude sleeping, or complex breathing patterns, auto-titration without clinical oversight may produce inadequate or excessive pressures that go unrecognised without formal data review.
A significant proportion of patients referred for sleep studies are found to have co-existing conditions that explain or contribute to their symptoms cardiac arrhythmias, obesity hypoventilation syndrome, hypothyroidism, or depression. A clinical assessment includes screening for these. Self-purchasing a CPAP machine bypasses this safety net entirely.
In approximately 5–15% of OSA patients, initiating CPAP therapy triggers treatment-emergent central apnoeas (TECA) a phenomenon where the brain’s respiratory drive is destabilised by the change in CO₂ dynamics. This typically resolves within the first few months but occasionally requires a change in device type. Without clinical monitoring, TECA can persist undetected while the patient believes therapy is working because they no longer snore.
Equipment purchased outside the NHS pathway is not eligible for NHS replacement, servicing, or review under the standard respiratory service framework. A self-purchased device that develops a fault, requires pressure adjustment, or needs replacement cannot typically be exchanged through NHS channels. All ongoing costs fall to the patient.
Some patients who self-purchase and self-treat feel better initially and delay seeking formal clinical assessment. If the self-prescribed therapy is sub-optimal, the patient continues on inadequate treatment without knowing it. Formal diagnosis also establishes a baseline AHI that is valuable for assessing long-term treatment response and for insurance and occupational health purposes.
Auto CPAP Without a Prescription: A Closer Look
The most common approach for those purchasing without a prescription is to buy an AutoCPAP (APAP) machine a device that automatically adjusts its pressure across a programmed range in response to detected breathing events, rather than delivering a fixed pressure. The reasoning is sound: an auto-titrating device should find the right pressure without needing a clinician to titrate it first.
This reasoning is partially correct and partially flawed, and understanding the distinction matters.
An AutoCPAP machine purchased without a prescription and used by a patient with straightforward moderate-to-severe OSA who happens to set the pressure range correctly will often produce meaningful improvement. The therapy will not be as precisely optimised as a clinically titrated prescription, but it will reduce the AHI and the patient will likely notice symptomatic improvement. For this patient, the main risks are the missed opportunity for formal diagnosis, the absence of monitoring, and the lack of clinical support if problems arise.
For a patient whose apparent OSA symptoms are actually caused by central sleep apnoea, hypoventilation, or a combination, the same approach carries meaningfully greater clinical risk and without a sleep study, there is no way to know which category applies.
The NHS Route: Why It Is Almost Always Worth Pursuing
The most common reason people consider bypassing the NHS pathway is waiting time. NHS sleep studies in some parts of England and Wales involve waits of six to eighteen months in heavily over-subscribed services. This is a real and frustrating barrier, and it is entirely understandable that patients with significant daytime sleepiness, functional impairment, or road safety concerns do not want to wait.
However, the NHS pathway delivers several things that self-purchase cannot:
- Free equipment: An NHS-prescribed CPAP device, mask, tubing, and humidifier are provided at no cost. Replacement parts are supplied through the NHS equipment service throughout the life of the prescription. For most patients, the lifetime equipment cost saving is several thousand pounds compared with private purchasing.
- Confirmed diagnosis: Your AHI is formally measured, your severity is documented, and your diagnosis is on your medical record. This matters for insurance purposes, for driving licence obligations if your apnoea is severe, and for occupational health assessments in safety-critical roles.
- Correct pressure setting: Your device is configured to a clinically appropriate pressure based on your titration study, not a default range.
- Clinical follow-up: Your therapy data is reviewed by a specialist team, settings are adjusted as needed, and complications are identified early.
- Legal driving obligations: Patients with severe OSA have a legal obligation under DVLA regulations to notify the DVLA and cease driving in certain circumstances until therapy is confirmed effective. Only a formal diagnosis and clinical confirmation of treatment response satisfies this obligation.
The Private Route: Fast, Legitimate, and Increasingly Accessible
For patients who can afford it and who cannot wait for the NHS, private diagnosis and prescription is a fully legitimate and increasingly accessible option in the UK. Private sleep studies whether home oximetry, respiratory polygraph, or full polysomnography are available through private hospitals, independent sleep clinics, and several online sleep health providers.
A private consultation with a respiratory physician or sleep specialist, followed by a home-based or in-clinic sleep study, diagnosis, pressure titration, and prescription. This is the gold-standard private route clinically equivalent to the NHS pathway but on your schedule.
Typical timeline: 2–6 weeks from referral to prescription.
Approximate cost: £500–£1,500 depending on study type and provider.
Several UK-based services now offer postal home sleep testing kits, remote analysis by qualified sleep clinicians, and online follow-up consultations. These are considerably cheaper than a full private clinic pathway and appropriate for straightforward OSA diagnosis in otherwise healthy adults.
Typical timeline: 1–3 weeks.
Approximate cost: £150–£400 for study and initial prescription.
Some GP practices operating enhanced respiratory services can refer directly for home sleep oximetry and offer initial CPAP prescriptions without a specialist sleep clinic. This pathway is available in certain areas through Primary Care Networks. Ask your GP whether this pathway exists locally.
Typical timeline: Variable 4–12 weeks.
Cost: Free on NHS if available in your area.
Registered UK CPAP suppliers including CPAP Studio can supply equipment to patients who already have a confirmed diagnosis and know their prescribed settings including those upgrading from NHS equipment to a newer model, purchasing a travel device, or replacing components. This is appropriate for established CPAP users, not for those seeking initial diagnosis.
Typical timeline: Immediate.
Cost: Equipment cost only.
Who Self-Purchasing Makes Sense For and Who It Does Not
The honest answer is that self-purchasing a CPAP machine without clinical assessment makes clinical sense for a narrow group of patients and carries meaningful risk for a broader group. Understanding which category you fall into is important before making a decision.
The NHS Waiting List Problem: What to Do While You Wait
If you are on an NHS waiting list for a sleep study and your symptoms are significantly impacting your daily life, the following options are worth considering while you wait short of purchasing and self-treating without diagnosis.
UK vs Other Countries: A Quick Comparison
| Country | Prescription Required? | Self-Purchase Possible? | Notes |
|---|---|---|---|
| United Kingdom | No - not legally required | Yes - legally permitted | CPAP is a Class IIa/IIb medical device, not prescription-only medicine |
| United States | Yes - legally required | Technically no, though grey-market imports occur | FDA requires prescription for CPAP sale; telemedicine routes exist |
| Australia | No - not required for purchase | Yes | Prescription required to access government subsidy (NDIS/PDS) |
| Canada | Varies by province | Generally yes | Prescription required for insurance reimbursement |
| Germany / EU | Yes - prescription required | Restricted | CPAP classified as prescription medical device under EU MDR |
